What is the future of immunotherapy in multiple myeloma?

被引：23
作者：
Rasche, Leo [1 ,2 ]
Hudecek, Michael [1 ]
Einsele, Hermann [1 ]
机构：
[1] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Oberdurrbacherstr 6, D-97080 Wurzburg, Germany
[2] Univ Klinikum Wurzburg, Mildred Scheel Early Career Ctr, Wurzburg, Germany
来源：
BLOOD | 2020年 / 136卷 / 22期
基金：
欧盟地平线“2020”;
关键词：
T-CELL THERAPY; NATURAL-KILLER-CELLS; ANTIBODY; DEXAMETHASONE; EXPRESSION; LEUKEMIA;
D O I：
10.1182/blood.2019004176
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The treatment of multiple myeloma (MM) is currently being redefined by humoral and cellular immunotherapies. For decades, there was limited belief in immune-based anti-MM therapy as a result of the moderate graft-versus-myeloma effect of allogeneic stem cell transplantation. Today, monoclonal antibodies comprise the new backbone of anti-MM therapy, and T-cell therapies targeting BCMA are emerging as the most potent single agents for MM treatment. Herein, we present our assessment of and vision for MM immunotherapy in the short and midterm.
引用
收藏
页码：2491 / 2497
页数：7
相关论文
共 50 条
[21]   Immunotherapy for multiple myeloma: new chances and hope [J].
Xu, Jingyu ;
An, Gang ;
Qiu, Lugui .
CANCER BIOLOGY & MEDICINE, 2023, 20 (10) :695-700
[22]   BCMA-targeted immunotherapy for multiple myeloma [J].
Yu, Bo ;
Jiang, Tianbo ;
Liu, Delong .
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
[23]   Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient [J].
Ghobrial, Irene ;
Hernandez Cruz, Calixto ;
Garfall, Alfred ;
Shah, Nina ;
Munshi, Nikhil ;
Kaufman, Jonathan ;
Boise, Lawrence H. ;
Morgan, Gareth ;
Adalsteinsson, Viktor A. ;
Manier, Salomon ;
Pillai, Rathi ;
Malavasi, Fabio ;
Lonial, Sagar .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (06) :332-344
[24]   Cellular immunotherapy as a therapeutic approach in multiple myeloma [J].
Liegel, Jessica ;
Avigan, David ;
Rosenblatt, Jacalyn .
EXPERT REVIEW OF HEMATOLOGY, 2018, 11 (07) :525-536
[25]   Immunogenic Targets for Specific Immunotherapy in Multiple Myeloma [J].
Zhang, Lu ;
Goetz, Marlies ;
Hofmann, Susanne ;
Greiner, Jochen .
CLINICAL & DEVELOPMENTAL IMMUNOLOGY, 2012,
[26]   CAR T therapies in multiple myeloma: unleashing the future [J].
Sheykhhasan, Mohsen ;
Ahmadieh-Yazdi, Amirhossein ;
Vicidomini, Rosario ;
Poondla, Naresh ;
Tanzadehpanah, Hamid ;
Dirbaziyan, Ashkan ;
Mahaki, Hanie ;
Manoochehri, Hamed ;
Kalhor, Naser ;
Dama, Paola .
CANCER GENE THERAPY, 2024, 31 (05) :667-686
[27]   Exploring cellular immunotherapy platforms in multiple myeloma [J].
Vo, Manh-Cuong ;
Jung, Sung-Hoon ;
Tran, Van-Dinh-Huan ;
Ruzimurodov, Nodirjon ;
Kim, Sang Ki ;
Nguyen, Xuan-Hung ;
Kim, Mihee ;
Song, Ga-Young ;
Ahn, Seo-Yeon ;
Ahn, Jae-Sook ;
Yang, Deok-Hwan ;
Kim, Hyeoung-Joon ;
Lee, Je-Jung .
HELIYON, 2024, 10 (06)
[28]   Humoral immunotherapy of multiple myeloma: perspectives and perplexities [J].
Di Bernardo, Andrea ;
Macor, Paolo ;
Guarnotta, Carla ;
Franco, Giovanni ;
Florena, Ada Maria ;
Tedesco, Francesco ;
Tripodo, Claudio .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2010, 10 (06) :863-873
[29]   Immune checkpoint inhibitors for multiple myeloma immunotherapy [J].
Liu, Zhaoyun ;
Xu, Xintong ;
Liu, Hui ;
Zhao, Xianghong ;
Yang, Chun ;
Fu, Rong .
EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2023, 12 (01)
[30]   Immunotherapy in Multiple Myeloma-Time for a Second Major Paradigm Shift [J].
Mohan, Meera ;
Hari, Parameswaran ;
Dhakal, Binod .
JCO ONCOLOGY PRACTICE, 2021, 17 (07) :405-+
12345